Two inverse 2-pyridyl-1,2,3-triazole "click" ligands, 2-(4-phenyl-1H-1,2,3-triazol-1-yl)pyridine and 2-(4-benzyl-1H-1,2,3-triazol-1-yl)pyridine, and their palladium(II), platinum(II), rhenium(I), and ruthenium(II) complexes have been synthesized in good to excellent yields. The properties of these inverse "click" complexes have been compared to the isomeric regular compounds using a variety of techniques. X-ray crystallographic analysis shows that the regular and inverse complexes are structurally very similar. However, the chemical and physical properties of the isomers are quite different. Ligand exchange studies and density functional theory (DFT) calculations indicate that metal complexes of the regular 2-(1-R-1H-1,2,3-triazol-4-yl)pyridine (R = phenyl, benzyl) ligands are more stable than those formed with the inverse 2-(4-R-1H-1,2,3-triazol-1-yl)pyridine (R = phenyl, benzyl) "click" chelators. Additionally, the bis-2,2'-bipyridine (bpy) ruthenium(II) complexes of the "click" chelators have been shown to have short excited state lifetimes, which in the inverse triazole case, resulted in ejection of the 2-pyridyl-1,2,3-triazole ligand from the complex. Under identical conditions, the isomeric regular 2-pyridyl-1,2,3-triazole ruthenium(II) bpy complexes are photochemically inert. The absorption spectra of the inverse rhenium(I) and platinum(II) complexes are red-shifted compared to the regular compounds. It is shown that conjugation between the substituent group R and triazolyl unit has a negligible effect on the photophysical properties of the complexes. The inverse rhenium(I) complexes have large Stokes shifts, long metal-to-ligand charge transfer (MLCT) excited state lifetimes, and respectable quantum yields which are relatively solvent insensitive.
The new low symmetry pyrazole-based tripodal tetraamine ligands 2-(1H-pyrazol-1-yl)-N,N-bis(1H-pyrazol-1-ylmethyl)ethanamine (bmpz) and 2-(1H-pyrazol-1-yl)-N-[2-(1H-pyrazol-1-yl)ethyl]-N-(1H-pyrazol-1-ylmethyl)ethanamine (bepz) have been prepared and characterised, as have metal complexes containing these ligands. X-ray crystal structures of [Co(bmpz)Cl](2)[CoCl(4)]·H(2)O, [Co(bmpz)MeCN](ClO(4))(2)·0.13H(2)O, [Zn(bmpz)MeCN](ClO(4))(2)·0.15H(2)O, [Zn(bepz)OH(2)](ClO(4))(2)·0.5H(2)O and [(Co(bepz)Cl)(2)]Cl(2)·6H(2)O confirm coordination of the intact tripodal ligands to the metal ions through all four N atoms. However, attempts to make Cu(2+) complexes containing bmpz and bepz gave, respectively, [Cu(7)Cl(2)]·0.2H(2)O and [Cu(8)Cl(2)] (7 = 1-(1H-pyrazol-1-yl)-N-(1H-pyrazol-1-ylmethyl)ethanamine, 8 = 2-(1H-pyrazol-1-yl)-N-[2-(1H-pyrazol-1-yl)ethyl]ethanamine), complexes containing the tridentate ligands 7 and 8 which are formed by loss of a pyrazolylmethyl arm from the appropriate tripodal ligand. This decomposition reaction occurs in protic solvents both in the presence and absence of metal ions, and is ascribed to the presence of an aminal functionality in the tripodal ligands. A possible mechanism for the decomposition, based on NMR and ESMS data, is suggested.
A family of tripodal tetraamine ligands incorporating two pyrazolyl and one 1,2,3-triazolyl donor arm have been synthesized in modest-to-excellent yields (42–90 %) using the copper(i)-catalyzed azide–alkyne cycloaddition (CuAAC) reaction. Mono-, bis-, and tris-tripodal ligand scaffolds were readily generated using this method. The coordination chemistry of the ligands with cobalt(iii) ions has been studied, and cobalt(iii) carbonato complexes of the ligands have been isolated and characterized spectroscopically and crystallographically. X-ray crystallography and NMR spectroscopy of the mono-metallic complexes showed that racemic mixtures of the cis-isomer are formed selectively. The di- and tri-metallic systems could not be crystallized, but NMR spectroscopy indicates that these compounds were isolated as mixtures of stereoisomers.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.